Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 16;12(12):2076.
doi: 10.3390/jpm12122076.

Pancreatic Cancer: Beyond Brca Mutations

Vincenzo Ricci  1 , Teresa Fabozzi  2 , Maria Anna Bareschino  1 , Emiddio Barletta  1 , Domenico Germano  1 , Immacolata Paciolla  1 , Vincenza Tinessa  1 , Antonio Maria Grimaldi  1
Affiliations
Review

Pancreatic Cancer: Beyond Brca Mutations

Vincenzo Ricci et al. J Pers Med. .

Abstract

Pancreatic cancer is the fourth-leading cause of cancer-related deaths worldwide. The outcomes in patients with pancreatic cancer remain unsatisfactory. In the current review, we summarize the genetic and epigenetic architecture of metastatic pancreatic cancer beyond the BRCA mutations, focusing on the genetic alterations and the molecular pathology in pancreatic cancer. This review focuses on the molecular targets for the treatment of pancreatic cancer, with a correlation to future treatments. The potential approach addressed in this review may lead to the identification of a subset of patients with specific biological behaviors and treatment responses.

Keywords: BRCA mutation; PARP inhibitor; metastatic pancreatic cancer; pathway; target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial and personal conflict of interest.

Figures

Figure 1
Figure 1
PARP enzyme inhibitors cause synthetic lethality in cancer cells with DNA repair defects or homologous repair defects.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Petersen G.M. Familial pancreatic cancer. Semin. Oncol. 2016;43:548–553. doi: 10.1053/j.seminoncol.2016.09.002. - DOI - PMC - PubMed
    1. Ryan D.P., Hong T.S., Bardeesy N. Pancreatic adenocarcinoma. N. Engl. J. Med. 2014;371:1039–10494. doi: 10.1056/NEJMra1404198. - DOI - PubMed
    1. Thota R., Pauff J.M., Berlin J.D. Treatment of metastatic pancreatic adenocarcinoma: A review. Oncology. 2014;28:70–74. - PubMed
    1. Biankin A.V., Waddell N., Kassahn K.S., Gingras M.-C., Muthuswamy L.B., Johns A.L., Miller D.K., Wilson P.J., Patch A.-M., Wu J., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399–405. doi: 10.1038/nature11547. - DOI - PMC - PubMed

LinkOut - more resources